Matthew Hunsucker, MD
Pulmonary Disease · Chapel Hill, NCNPI 1285012625
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,858 of the $9,431 with a category attached, or 62.1%. 30 manufacturers reported payments, led by Chiesi USA, Inc. at 37.3% of the total. 2025 is the largest year on record at $4,829, more than ten times the $421 reported in 2021.
Across 326 payments — averaging $28.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Chiesi USA, Inc.$4K
- United Therapeutics Corporation$811
- AstraZeneca$807
- GSK$665
- Boehringer Ingelheim$520
- Sanofi$374
- plus $3K from 24 others
Across 91 payments — averaging $2580.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$235K
What the payments were for
- Consulting fees$2,50027%
- Travel & lodging$92610%
- Food & beverage$5,85862%
- Education$1472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Chiesi USA, Inc. | 6 | $3,522 |
| United Therapeutics Corporation | 62 | $811 |
| AstraZeneca | 43 | $807 |
| GSK | 42 | $665 |
| Boehringer Ingelheim | 28 | $520 |
| Sanofi | 13 | $374 |
| Regeneron Healthcare Solutions, Inc. | 9 | $274 |
| Mylan Specialty L.p. | 17 | $264 |
| Amgen | 12 | $252 |
| Actelion Pharmaceuticals US, Inc. | 12 | $244 |
| Merck | 12 | $237 |
| Grifols USA, LLC | 10 | $235 |
| Verona Pharma, Inc. | 9 | $183 |
| Baxter Healthcare | 5 | $135 |
| AbbVie | 8 | $127 |
| Electromed, Inc. | 9 | $122 |
| Insmed, Inc. | 4 | $112 |
| Davol Inc. | 2 | $106 |
| Breas Medical, Inc. | 1 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $58 |
| Teva Pharmaceuticals USA, Inc. | 3 | $55 |
| Shionogi Inc | 3 | $52 |
| Novartis | 3 | $50 |
| Viatris Specialty LLC | 2 | $35 |
| Genentech USA, Inc. | 2 | $32 |
| Pfizer | 2 | $32 |
| Harmony Biosciences LLC | 1 | $21 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $17 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
| Bayer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$100
How this compares
$9,431 in reported general payments places this provider in the 75th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 28 | $756,759 |
| Tyvaso DpiTreprostinil | 22 | $515,836 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 301 | $243,461 |
| OpsumitMacitentan | 17 | $214,772 |
| WinrevairSotatercept-Csrk | 11 | $208,740 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 175 | $139,653 |
| Ambrisentan | 13 | $94,266 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 168 | $90,292 |
| Fasenra PenBenralizumab | 13 | $68,522 |
| Dupixent SyringeDupilumab | 13 | $52,038 |
| XolairOmalizumab | 12 | $33,751 |
| Breo ElliptaFluticasone/Vilanterol | 71 | $33,640 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 60 | $33,162 |
| EliquisApixaban | 42 | $31,389 |
| SymbicortBudesonide/Formoterol Fumarate | 104 | $27,877 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $244 | $971,53145 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $665 | $310,263432 claims |
| MerckWinrevair | $237 | $208,74011 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $807 | $183,716317 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $520 | $105,221197 claims |
| PfizerEliquis | $32 | $31,38942 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Chapel Hill
- James DonohueChapel Hill$271K
- Hubert FordChapel Hill$94K
- Scott DonaldsonChapel Hill$47K
- Michael KnowlesChapel Hill$36K
- Mary DanielsChapel Hill$15K
- Michael PritchettPinehurst$1.3M
- Michael WertGreensboro$412K
- Eugene BleeckerWinston Salem$357K
- Bradley IcardPinehurst$299K
- Eric MeltzerDurham$262K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.